SCHEMBL23167492

SCHEMBL23167492

COC(=O)c1cnc2c(ccn2Cc2ncc(Br)cc2F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.48
▸ FGFR4 P22455 2/20 0.48
▸ HDAC3 O15379 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ PSMD14 O00487 1/20 0.36
▸ ENPP3 O14638 2/20 0.35
▸ ENPP1 P22413 2/20 0.35
▸ METAP2 P50579 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ USP2 O75604 1/20 0.33
▸ MAPK10 P53779 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ APOBEC3A P31941 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ APOBEC3G Q9HC16 1/20 0.33
▸ YTHDC1 Q96MU7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23167363 0.87 FGFR1 (0.48) FGFR1FGFR4HDAC3HDAC2ENPP3
SCHEMBL25138359 0.82 HPGDS (0.42) KDM4EALDH1A1HPGDCYP3A4CYP2C9
SCHEMBL23167484 0.82 FGFR1 (0.45) FGFR1FGFR4HDAC3HDAC2
SCHEMBL16804263 0.79 FGFR1 (0.54) FGFR1FGFR4HDAC3HDAC2USP2
SCHEMBL31403654 0.77 PSMD14 (0.45) PSMD14KDM4EALDH1A1POLBHPGD
SCHEMBL23885053 0.75 PSMD14 (0.43) PSMD14KDM4EALDH1A1POLBHPGD
SCHEMBL18108859 0.73 FGFR1 (0.46) FGFR1FGFR4ENPP3ENPP1KDM4E
SCHEMBL29779623 0.73 HDAC3 (0.41) HDAC3HDAC2HDAC8HDAC6CYP2C9
SCHEMBL23167369 0.73 HDAC3 (0.41) HDAC3HDAC2HDAC8HDAC6CYP2C9
SCHEMBL25211173 0.70 PSMD14 (0.39) PSMD14KDM4EALDH1A1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2023-04-20 — — US disclosed
EP-4037670-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF Tenaya Therapeutics, Inc. (US) 2022-08-10 — — EP disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 — — WO disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF SLC28A1, SLC5A1, SLC9A5 FGFR1 26/4885FGFR4 194/4885HDAC3 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback